Vascular Ehlers-Danlos Syndrome (VEDS)Symptoms, Doctors, Treatments, Advances & More
Vascular Ehlers-Danlos Syndrome (VEDS) Overview
Learn About Vascular Ehlers-Danlos Syndrome (VEDS)
Xavier Jeunemaitre practices practicing medicine in Paris, France. Mr. Jeunemaitre is rated as an Elite expert by MediFind in the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Vascular Ehlers-Danlos Syndrome (VEDS), Ehlers-Danlos Syndrome (EDS), Fibromuscular Dysplasia (FMD), Pseudohypoaldosteronism Type 1, and Angioplasty.
The Association Of University Physicians
Peter Byers is a Medical Genetics provider practicing medicine in Seattle, Washington. Dr. Byers is rated as an Elite provider by MediFind in the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Ehlers-Danlos Syndrome (EDS), Vascular Ehlers-Danlos Syndrome (VEDS), Osteogenesis Imperfecta, and De Barsy Syndrome. Dr. Byers is currently accepting new patients.
Salma Adham practices practicing medicine in Montpellier, France. Ms. Adham is rated as an Elite expert by MediFind in the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). She is also highly rated in 2 other conditions, according to our data. Her clinical expertise encompasses Vascular Ehlers-Danlos Syndrome (VEDS), Ehlers-Danlos Syndrome (EDS), Pseudoxanthoma Elasticum, and Meige Disease.
Summary: This research study will investigate whether participants with vascular Ehlers-Danlos syndrome (vEDS), a rare inherited condition, have problems with the way the participants' body stores and uses fat (adipose tissue). vEDS is caused by changes in a gene called COL3A1, which makes a protein important for the structure of many tissues. While vEDS is best known for making blood vessels fragile, ther...
Summary: This is a prospective, Phase 3, randomized, double-blind, placebo-controlled efficacy study to evaluate celiprolol in patients genetically confirmed as COL3A1-positive vEDS using a decentralized clinical trial design.